Skip to main content
Biohit Oyj logo

Biohit Oyj — Investor Relations & Filings

Ticker · BIOBV ISIN · FI0009005482 LEI · 74370089ATTSNBXJVT29 HE Manufacturing
Open in API
Filings indexed 992 across all filing types
Latest filing 2022-01-13 Report Publication Anno…
Country FI Finland
Listing HE BIOBV

About Biohit Oyj

https://www.biohithealthcare.com/en/

Biohit Oyj is a global biotechnology company that develops, manufactures, and markets innovative diagnostic products and services. The company specializes in tools for the early diagnosis and prevention of diseases, with a primary focus on gastroenterology. Its key offerings include the GastroPanel® blood test for assessing stomach health and screening for risks of gastric cancer, as well as diagnostic tests for conditions such as Helicobacter pylori infection. Operating under the mission "Innovating for Health," Biohit's products are designed to support medical research, facilitate early and accurate diagnosis, and improve patient quality of life.

Recent filings

Filing Released Lang Actions
Biohitin taloudellinen tiedottaminen ja yhtiökokous vuonna 2022
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) that outlines the company's financial reporting calendar for the upcoming year, including dates for the release of the annual report, interim reports, and the annual general meeting. It does not contain the actual financial reports themselves, but rather serves as a schedule announcement. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2022-01-13 Finnish
01130799.pdf
Report Publication Announcement Classification · 100% confidence The document is a short announcement (1670 characters) detailing the scheduled dates for the release of future financial reports (Financial Statements, Annual Report, Half-year report) and the planned date for the Annual General Meeting. It does not contain the actual reports themselves, but rather serves as a calendar/notification of publication dates. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2022-01-13 English
Biohit Oyj’s Financial Reporting and Annual General Meeting in 2022
Report Publication Announcement Classification · 100% confidence The document is a short announcement (3,457 characters) that outlines the company's financial calendar for the upcoming year, including dates for the release of financial statements, the Annual Report, and the Annual General Meeting. It does not contain the actual reports themselves but rather informs stakeholders of when these reports will be published. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA).
2022-01-13 English
12093815.pdf
Share Issue/Capital Change Classification · 95% confidence The document is a stock exchange release from Biohit Oyj announcing the creation of a new option scheme for key personnel, including the CEO and other directors. While it mentions specific directors receiving options, it is a corporate announcement regarding the issuance of new equity-based incentives (option rights) rather than a report of personal market transactions by directors (DIRS). As it relates to the issuance of new potential shares and capital structure changes via an option scheme, it falls under the category of share issue/capital change.
2021-12-09 English
Biohit Oyj Board of Directors decided on new option scheme
Share Issue/Capital Change Classification · 95% confidence The document is a stock exchange release announcing a new option scheme for key personnel, including the CEO and other directors. This involves the issuance of new option rights which are a form of capital change or incentive structure. While it involves directors, it is not a report of a personal transaction (DIRS) but rather a corporate announcement of a new incentive plan. Given the nature of the announcement regarding share-based compensation and potential future share issuance, it fits best under 'Share Issue/Capital Change' (SHA).
2021-12-09 English
12093807.pdf
Share Issue/Capital Change Classification · 95% confidence The document is a stock exchange release from Biohit Oyj announcing the board's decision to implement a new stock option program for key personnel. It details the number of options, exercise prices, and the specific recipients (executives). While it involves share-based incentives, it is fundamentally an announcement regarding the company's capital structure and incentive schemes, which falls under the 'Share Issue/Capital Change' category as it relates to the potential future issuance of shares via options.
2021-12-09 Finnish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.